Literature DB >> 24852243

Deep sequencing detects very-low-grade somatic mosaicism in the unaffected mother of siblings with nemaline myopathy.

Satoko Miyatake1, Eriko Koshimizu1, Yukiko K Hayashi2, Kazushi Miya3, Masaaki Shiina4, Mitsuko Nakashima1, Yoshinori Tsurusaki1, Noriko Miyake1, Hirotomo Saitsu1, Kazuhiro Ogata4, Ichizo Nishino5, Naomichi Matsumoto6.   

Abstract

When an expected mutation in a particular disease-causing gene is not identified in a suspected carrier, it is usually assumed to be due to germline mosaicism. We report here very-low-grade somatic mosaicism in ACTA1 in an unaffected mother of two siblings affected with a neonatal form of nemaline myopathy. The mosaicism was detected by deep resequencing using a next-generation sequencer. We identified a novel heterozygous mutation in ACTA1, c.448A>G (p.Thr150Ala), in the affected siblings. Three-dimensional structural modeling suggested that this mutation may affect polymerization and/or actin's interactions with other proteins. In this family, we expected autosomal dominant inheritance with either parent demonstrating germline or somatic mosaicism. Sanger sequencing identified no mutation. However, further deep resequencing of this mutation on a next-generation sequencer identified very-low-grade somatic mosaicism in the mother: 0.4%, 1.1%, and 8.3% in the saliva, blood leukocytes, and nails, respectively. Our study demonstrates the possibility of very-low-grade somatic mosaicism in suspected carriers, rather than germline mosaicism.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  ACTA1; Deep resequencing; Low-grade somatic mosaicism; Nemaline myopathy; Next-generation sequencer

Mesh:

Year:  2014        PMID: 24852243     DOI: 10.1016/j.nmd.2014.04.002

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  7 in total

1.  Germline mosaicism is a pitfall in the diagnosis of "sporadic" X-linked Alport syndrome.

Authors:  Takayuki Okamoto; Kandai Nozu; Kazumoto Iijima; Tadashi Ariga
Journal:  J Nephrol       Date:  2018-07-30       Impact factor: 3.902

2.  Next-generation sequencing discloses a nonsense mutation in the dystrophin gene from long preserved dried umbilical cord and low-level somatic mosaicism in the proband mother.

Authors:  Mariko Taniguchi-Ikeda; Yasuhiro Takeshima; Tomoko Lee; Masahiro Nishiyama; Hiroyuki Awano; Mariko Yagi; Ai Unzaki; Kandai Nozu; Hisahide Nishio; Masafumi Matsuo; Hiroki Kurahashi; Tatsushi Toda; Ichiro Morioka; Kazumoto Iijima
Journal:  J Hum Genet       Date:  2016-01-07       Impact factor: 3.172

3.  Next-generation sequence-based preimplantation genetic testing for monogenic disease resulting from maternal mosaicism.

Authors:  Xiao Hu; Wen-Bin He; Shuo-Ping Zhang; Ke-Li Luo; Fei Gong; Jing Dai; Yi Zhang; Zhen-Xing Wan; Wen Li; Shi-Min Yuan; Yue-Qiu Tan; Guang-Xiu Lu; Ge Lin; Juan Du
Journal:  Mol Genet Genomic Med       Date:  2021-05-04       Impact factor: 2.183

Review 4.  Unrevealed mosaicism in the next-generation sequencing era.

Authors:  Marzena Gajecka
Journal:  Mol Genet Genomics       Date:  2015-10-19       Impact factor: 3.291

5.  Novel mutations in PAX6, OTX2 and NDP in anophthalmia, microphthalmia and coloboma.

Authors:  Brett Deml; Linda M Reis; Emmanuelle Lemyre; Robin D Clark; Ariana Kariminejad; Elena V Semina
Journal:  Eur J Hum Genet       Date:  2015-07-01       Impact factor: 4.246

6.  Identification of paternal germline mosaicism by MicroSeq and targeted next-generation sequencing.

Authors:  Congling Dai; Dehua Cheng; Weina Li; Sicong Zeng; Guangxiu Lu; Qianjun Zhang
Journal:  Mol Genet Genomic Med       Date:  2020-07-09       Impact factor: 2.183

7.  ADCY5 mutations are another cause of benign hereditary chorea.

Authors:  Niccolo E Mencacci; Roberto Erro; Sarah Wiethoff; Joshua Hersheson; Mina Ryten; Bettina Balint; Christos Ganos; Maria Stamelou; Niall Quinn; Henry Houlden; Nicholas W Wood; Kailash P Bhatia
Journal:  Neurology       Date:  2015-06-17       Impact factor: 9.910

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.